Anteris Technologies Announces First Successful Implantation

BRISBANE, Australia & MINNEAPOLIS, July 31, 2023--Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of biomimetic heart valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve shaped to mimic the performance of a native human aortic valve, announces that the DurAVR™ THV was used for the first time in a valve-in-valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).

Related Keywords

Australia , Canada , United States , Anteri Com , Chris Meduri , Wayne Paterson , Malini Chatterjee , Dejan Toracki , Anita Asgar , Blueprint Life Science Group , Health Canada , Facebook , Journal Of The American College Cardiology , Diabetes Institute , Linkedin , Structural Heart Program , Corporate Development , Institut De Cardiologie Montreal , Anteris Technologies Chief Medical Officer , Anteris Technologies , Business Wire , Delivery System , Disease Prevalence , Transcatheter Aortic Valve Replacement , American College , Baker Heart , Fracturing Bioprosthetic , Shows Increased Mortality Risk , Modest Hemodynamic Benefit , Chief Executive , Aortic Valve Replacement , Aortic Valve , Bhv , R Anita Asgar , Interis , Heart Valve , Shiv , Aortic Stenosis ,